Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
Combination of PEG interferon and ribavirin is the standard treatment of chronic hepatitis C.
Efficacy of this treatment has never been evaluated in HCV-HIV infected patients, who have
previously been treated with a first line anti-HCV treatment. The purpose of the study is to
evaluate the combination PEG interferon alfa2a-ribavirin in HIV-infected patients with
chronic hepatitis C pretreated with interferon alone or interferon combined with ribavirin.
The patients receive a dose of 180 µg of PEGASYS once a week and 800 to 1200 mg/day of
ribavirin (according to weight) for 48 weeks. Primary outcome of the study is a sustained
virological response, defined as an undetectable HCV RNA level 24 weeks after the end of
anti-HCV treatment.